7Burik D, Nackel JG. Diagnosis-related groups:tool for manage- ment[J]. Hosp Health Serv Adm, 1981, 26(1): 25-40.
8Francis H,Roger France. Case mix use in 25 countries: a mi- gration success but international comparisons failure[J]. Inter- national Journal of Medical Informatics, 2003, 70: 215-219.
9Barbara OW, Molly S. Evaluation of severity-adjusted DRG sys- tems: addendum to the interim repord-EB/OL3. [2010-05-17]. ht- tps://www. cms gov/reports/downloads/WR434Z1, pdf.
10Palmer G, Reid B, Aisbett C, et al. Evaluating the performance of the Australian National Diagnosis Related Groups[R]. Syd- ney: The Centre for Hospital Management and Information Systems Research, University of New South Wales, 1997.
4Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res, 1998, 17: 77-98.
5Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res,2002, 21: 127-144.
6Lashkari K, Rahimi N, Kazlauskas A. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci, 1999, 40: 149-156.
7Mitamura Y, Takeuchi S, Matsuda A, et al. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy. Am J Ophthalmol, 2000,129: 678-680.
8Jin M, Barron E, He S, et al. Regulation of RPE intercellular junction integrity and function by hepatocyte growth factor. Invest Ophthalmol Vis Sci, 2002,43:2782-2790.
9He PM, He S, Garner JA, et al. Retinal pigment epithelial cells secrete and respond to hepatocyte growth factor. Biochem Biophys Res Commun, 1998, 249: 253-257.
10Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology, 2001,108: 1179-1183.
